ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS

Informazioni relative al progetto

UNITE4TB

ID dell’accordo di sovvenzione: 101007873

DOI 10.3030/101007873

Data della firma CE 29 Giugno 2021

Data di avvio 1 Giugno 2021

Data di completamento 31 Maggio 2028

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale € 185 000 000,00

Contributo UE € 92 500 000,00

Coordinato da

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Netherlands

Risultati finali

Documents, reports (6)

Report of kick-off meeting

Report of kickoff meeting

Communication and dissemination plan
Establish CAG
Establish SAB and RAB
Report of first annual consortium meeting
Establish EAB

Other (2)

Inaugural meeting with communication professionals of the partners in the consortium
Establish Young Investigators Group

Websites, patent fillings, videos etc. (1)

Visual identity and communication toolkit, including project website

Visual identity and communication toolkit including project website

Pubblicazioni

Peer reviewed articles (5)

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Autori: Keutzer L, You H, Farnoud A, Nyberg J, Wicha SG, Maher-Edwards G, Vlasakakis G, Moghaddam GK, Svensson EM, Menden MP, Simonsson USH, On Behalf Of The UNITE4TB Consortium
Pubblicato in: Pharmaceutics, 2022, ISSN 1999-4923
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14081530

Tuberculosis: current challenges and beyond

Autori: Raquel Villar-Hernández, Arash Ghodousi, Olha Konstantynovska, Raquel Duarte, Christoph Lange, Mario Raviglione on behalf of the UNITE4TB Consortium
Pubblicato in: Breath, 2023, ISSN 2073-4735
Editore: European Respiratory Society
DOI: 10.1183/20734735.0166-2022

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies

Autori: Heyckendorf J, Georghiou SB, Frahm N, Heinrich N, Kontsevaya I, Reimann M, Holtzman D, Imperial M, Cirillo DM, Gillespie SH, Ruhwald M, Consortium UNITE4TB
Pubblicato in: Clinical Microbiology Reviews, Numero 21 March 2022, 2022, Pagina/e n/a, ISSN 1098-6618
Editore: American Society for Microbiology
DOI: 10.1128/cmr.00227-21

Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries

Autori: Anca Vasiliu, Antonia Morita Iswari Saktiawati, Raquel Duarte, Christoph Lange, Daniela Maria Cirillo on behalf of the UNITE4TB Consortium
Pubblicato in: Breath, 2023, ISSN 2073-4735
Editore: European Respiratory Society
DOI: 10.1183/20734735.0226-2022

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Autori: Mockeliunas L, Faraj A, van Wijk RC, Upton CM, van den Hoogen G, Diacon AH, Simonsson USH
Pubblicato in: Front. Pharmacol., 2023, ISSN 1663-9812
Editore: Frontiers Media S.A.
DOI: 10.3389/fphar.2023.1150243

Non-peer reviewed articles (1)

UNITE4TB: a new consortium for clinical drug and regimen development for TB

Autori: Boeree, M. J.; Lange, C.; Thwaites, G; Paton, N ; de Vrueh, R.; Barros, D.; Hoelscher, M.; on behalf of the UNITE4TB Consortium
Pubblicato in: International Union Against Tuberculosis and Lung Disease, Numero Volume 25, Number 11, 1 November 2021, 2021, Pagina/e 886-889, ISSN 1027-3719
Editore: International Union Against Tuberculosis And Lung Disease/Union Internationale Contre la Tuberculose et les Maladies Respiratories
DOI: 10.5588/ijtld.21.0515